Source: CureToday articles
Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, including GIST and some leukemias.
Recent Content
- Going with the Flow: Updates in Diabetes and Chronic Kidney Disease
- Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment
- Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis
- ASCO 2025: Pre-Treatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost
- Guiding Light: A Journey of Support and Hope
- Pneumococcal 15-Valent Conjugate Vaccine Provides Heightened Protection Against Certain Serotypes Compared With PCV13
- Condition Watch: Vitamins
- HER2 and HER3 in NSCLC: The Latest ADC Data and NCCN Guideline Updates
- Tracing a Five-Generation Cancer Legacy Through Genetic Discovery
- Patritumab Deruxtecan BLA Withdrawn in Non-Small Cell Lung Cancer